Abstract
Introduction: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients.
Methods: This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100 mg/100 mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated.
Results: The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital.
Conclusion: Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
【초록키워드】 COVID-19, Treatment, coronavirus disease, Coronavirus disease 2019, Efficacy, Open-label, hospital, Ritonavir, protease, RT-PCR, HCV, approved drugs, adverse outcome, China, Real-time PCR, Hepatitis, outbreak, CT scan, hepatitis C virus, Patient, hepatitis C, CT scans, inhibitor, patients, therapeutic options, primary endpoint, COVID-19 patient, Safe, therapeutic option, chronic hepatitis, approved drug, naïve, treat, Effect, Danoprevir, enrolled, occurred, evaluated, approved, median, per day, discharged, 【제목키워드】 HCV, Protease inhibitor, clinical study, COVID-19 patient, treat,